Amgen clears key resistance level, shares range between support and new highs
26.06.2026 - 10:53:31 | ad-hoc-news.de
By Daniel Hoffmann, Chart & Technicals desk. Reviewed prior to publication on 2026-06-26, 10:52.
Amgen Inc. (US0311621009) closed the latest Nasdaq session at 352.82 US dollars on June 25, 2026, according to TradingKey data. The biotech heavyweight, a member of the S&P 500 and Nasdaq-100, trades within a defined technical range that currently attracts swing traders.
What the technicals show
Recent technical analysis places Amgen between a support level at 330.38 US dollars and resistance around 367.18 US dollars, framing the stock in a range-bound pattern. The current price momentum score stands at 9.01, ranking the company 55th within 157 pharmaceuticals names covered by TradingKey.
Moving-average indicators are tilted toward the bullish side. Based on short- to long-term moving averages from MA5 through MA200, Amgen generates six buy signals and no sell signals in the TradingKey model. Additional technical metrics show three buy signals and one sell signal, underpinning the overall positive bias. A separate quantitative forecast from Pandaforecast sees the stock near 356.62 US dollars by July 2, 2026, with an optimistic short-term target of 360.12 US dollars and a pessimistic mark at 353.56 US dollars, highlighting expected volatility of about 1.8 percent.
How the shares trade on Nasdaq
On June 25, 2026, Amgen shares on Nasdaq opened at 350.06 US dollars, reached an intraday high of 359.10 US dollars, and stayed above the session low of 350.06 US dollars, as aggregated by Pandaforecast from US quote feeds. The closing print at 352.82 US dollars reflected a gain of 0.40 percent versus the prior day, while extended trading after the close saw quotes around 355.66 US dollars, up roughly 0.80 percent from the official close.
Daily trading volume in the latest session was reported at 2,341,847 shares, a level that signals active investor interest without indicating unusual turnover. From a valuation angle, TradingKey reports a market capitalization of about 190.42 billion US dollars and a trailing price-earnings ratio of 24.36, placing Amgen toward the higher end of large-cap biotech valuations but below some high-growth peers such as Moderna or Vertex Pharmaceuticals. MarketBeat notes that Amgen’s shares have recently moved in tandem with broader health care indices, reflecting sector-wide scrutiny over clinical data integrity and pricing rather than company-specific shocks.
More news and data on the Amgen shares
All current stories, price information and background on Amgen are available in the dedicated topic section and via the company’s investor relations pages.
The business behind the stock
Amgen is one of the largest independent biotechnology companies globally, with a focus on therapies for serious illnesses in oncology, hematology, cardiovascular disease and immunology. Flagship products include anti-inflammatory agents and oncology biologics, as well as an expanding portfolio of biosimilars that target established blockbuster molecules from rivals such as AbbVie and Roche. The company reported first-quarter 2026 earnings on April 30, 2026, posting earnings per share of 5.15 US dollars, beating the analyst consensus of 4.77 US dollars by 0.38 US dollars.
For full-year 2026, Amgen has guided toward earnings per share in a range of 21.70 to 23.10 US dollars and revenues between 37.1 and 38.5 billion US dollars, according to MarketBeat’s summary of the April 30 guidance update. The midpoint of the revenue range, 37.8 billion US dollars, aligns closely with the consensus revenue estimate of 37.8 billion US dollars, underlining management’s conservative stance in a competitive and regulated market. In parallel, the company continues to invest in research and development for next-generation oncology agents and inflammation therapies, supported by strong free cash flow and disciplined capital allocation.
Where the shares trade today
Amgen shares (US0311621009) trade on Nasdaq at 352.82 US dollars as of the close on 2026-06-25, 16:00 Eastern Time, with extended trading quotes reported around 355.66 US dollars later in the evening. That price puts the stock toward the upper half of its recent range between technical support near 330.38 US dollars and resistance around 367.18 US dollars, as observed on TradingKey.
Key data on the Amgen shares
- Company: Amgen Inc.
- ISIN: US0311621009
- WKN: 867074
- Ticker: AMGN
- Trading venue: Nasdaq
- Price (as of 2026-06-25, 16:00): 352.82 USD
- Market cap: 190.42 billion USD (as of 2026-06-25)
- Sector / industry: Health Care - Biotechnology
- Index membership: S&P 500, Nasdaq-100
- Next earnings date: not officially scheduled
Disclaimer: This text is for informational purposes only and does not constitute investment advice, a recommendation to buy or sell securities, or a solicitation of any transaction. All data were obtained from sources deemed reliable at the time of publication but may change without notice. Investors should conduct their own research and, where appropriate, consult a licensed financial advisor.
